QuidelOrtho Corp. Stock
QuidelOrtho Corp. Stock
The QuidelOrtho Corp. stock is trending slightly upwards today, with an increase of €0.000 (0.540%) compared to yesterday's price.
With 6 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
Based on the current price of 37.2 € the target price of 75 € shows a potential of 101.61% for QuidelOrtho Corp. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the QuidelOrtho Corp. stock. Criterium "Innovation" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of QuidelOrtho Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| QuidelOrtho Corp. | 0.540% | - | -5.584% | -54.423% | -45.149% | -58.648% | - |
| Boston Scientific | 0.740% | -0.730% | 7.937% | 42.647% | 32.193% | 88.001% | 105.687% |
| Waters Corp. | 2.070% | 2.648% | -5.418% | 10.556% | -1.159% | 18.452% | 53.077% |
| Illumina Inc. | -5.450% | -4.165% | -7.092% | -38.410% | -14.770% | -65.786% | -62.274% |
Comments
QuidelOrtho Co. (NASDAQ: QDEL) had its "sell" rating re-affirmed by analysts at UBS Group AG. They now have a $42.00 price target on the stock, down previously from $70.00.
Show more
Ratings data for QDEL provided by MarketBeat
QuidelOrtho Co. (NASDAQ: QDEL) had its price target lowered by analysts at Royal Bank of Canada from $130.00 to $81.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for QDEL provided by MarketBeat
QuidelOrtho Co. (NASDAQ: QDEL) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. They now have a $37.00 price target on the stock, down previously from $66.00.
Show more
Ratings data for QDEL provided by MarketBeat
News
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and
QuidelOrtho To Report First Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a